Kornimate/medical-research-clean huggingface dataset:
comparison of malassezia spp proportions in inflammatory and non inflammatory facial acne vulgaris lesions

Conditions: Acne Vulgaris

Summary: acne vulgaris (av) is a common inflammatory condition involving pilosebaceous unit. the pathogenesis of acne is multifactorial and skin microbiome is considered to be one of the key factors that aggravate inflammation. malassezia spp is normal flora on the skin and several studies have reported its corelation with inflammatory av lesion. malassezia have higher lipase activity compared to propionibacterium acnes which triggers an increase in free fatty acid and glycerol, the chemotactic factors towards neutrophils and inducing inflammation in av. malassezia folliculitis (mf) is sometimes confused with and may present together with av. pruritus usually presents in mf but some studies also reported itching as common symptom in av. the objectives of this study were to identify the presence and the distribution of malassezia spp. in facial av lesions, to compare the distribution of malassezia spp. between inflammatory and non-inflammatory lesions and to identify the association between malassezia spp in acne lesions and pruritus symptom.

this study used cross sectional design study. subjects with eligible criteria were included. subjects were divided into subjects with inflammatory lesions and subjects with non inflammatory lesions. physical examination consisted of assesment of av severity (using lehman criteria) and presence of pruritus based on visual analog scale. clinical documetations were taken. follicular content of four inflammatory lesions or four non inflammatory lesions were collected for microscopic examination with koh solution and fungal culture examination (using chromagar malassezia, dextrose saboraud agar (dsa), and tween 60-esculin agar). the presence of malassezia spp and its spore load in both groups were assesed and analyzed for its corelation with av severity and presence of pruritus.

Eligibility criteria:
inclusion criteria: * subjects with age of 15-49 years with av and the presence of at least four inflammatory and four non-inflammatory lesions exclusion criteria: * subjects with prior topical retinoid acid or topical antifungal medication within the past two weeks, systemic antibiotic or antifungal use within the past month, and corticosteroid use within the past six months

Keywords: acne lesion, malassezia spp, skin microbiome, pruritus
can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Conditions: Obesity, Childhood; NAFLD

Summary: the incidence of non-alcoholic fatty liver disease (nafld) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process. this study aimed to determine the role of fecal calprotectin (fcp) as an inflammatory biomarker in course of obesity and nafld.

obesity is a significant public health issue worldwide. with the increasing prevalence of obesity, the prevalence of metabolic syndrome in adolescents is also on the rise. non-alcoholic fatty liver disease (nafld), a major cause of chronic liver disease, is the hepatic component of metabolic syndrome. the prevalence of nafld is not precisely known, but in some studies, it is between 22.5% and 52.8% in children with obesity, constituting 2.6% of all children. although the mechanisms involved in the development of obesity-related metabolic complications and nafld are not well understood, it is believed that intestinal inflammation, changes in the microbiota, and alterations in the gut-liver axis (gla) may play a role in the development of low-grade chronic inflammation in nafld associated with obesity. fecal calprotectin (fcp), which has become increasingly important in demonstrating intestinal inflammation in recent years, is a widely used test, particularly in the diagnosis and monitoring of inflammatory bowel disease and various gastrointestinal disorders. in our study, the utility of fcp as an inflammatory biomarker in the course of nafld in obese adolescents has been investigated. the study was approved by our hospital's ethics committee in 15.11.2022 and another ethics committee approval was taken in 08.06.2023 for title change of study. this study conducted under the helsinki declaration.

Eligibility criteria:
inclusion criteria: * 10-18 years old healthy adolescents for control group * children aged 10-18 years without any additional diseases, bmi\>2 sd, no hepatosteatosis detected by ultrasonography (usg), and alanine aminotransferase (alt) levels within normal limits were included in the obese group * children aged 10-18 years without any additional diseases, bmi\>2 sd, hepatosteatosis detected by ultrasonography (usg), and alanine aminotransferase (alt) levels higher than normal limits adjusted for gender were included in the obese + nafld group exclusion criteria: * diseases other than obesity and nafld
evaluation of safety and efficacy of tug (therapeutic ultrasound for glaucoma) in the treatment of primary open angle glaucoma or ocular hypertension

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: the purpose of this study is to evaluate whether the tug device is safe and effective in patients with primary open angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosis of primary open angle glaucoma or ocular hypertension in both eyes * be willing to discontinue disallowed products and/or medications during the period indicated prior to participation or throughout the study * be willing to provide written informed consent * be willing and able to follow instructions * a negative urine pregnancy test and agree to an acceptable form of contraception for the duration of the study (if female of childbearing potential) exclusion criteria: * any form of glaucoma other than primary open angle glaucoma or ocular hypertension in either eye * prior or anticipated concurrent use of an investigational drug or device * be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive pregnancy test * have a condition (ocular or systemic) or a situation which, in the investigator's opinion, may put the subject at increased risk, may confound study data, or may interfere significantly with the subject's study participation
fluid optimisation in laparoscopic colorectal procedures

Conditions: Perioperative Complication

Summary: goal-directed fluid therapy (gdft) with hemodynamic monitoring may not be of benefit to all elective patients undergoing major abdominal surgery, particularly those managed in enhanced recovery after surgery protocols (eras) setting.

our study compared two groups of patients undergoing elective laparoscopic colorectal surgery: a control group (cg) in which standard haemodynamic monitoring was used, and a study group (sg) in which extended haemodynamic monitoring was applied with appropriate intraoperative interventions. differences in intraoperative fluid management, hospital stay, and postoperative morbidity were observed.

Eligibility criteria:
inclusion criteria: * patients, undergoing elective laparoscopic colorectal surgery exclusion criteria: * patients with cardiac arrhythmias

Keywords: postoperative complications, intraoperative monitoring, haemodynamic monitoring, laparoscopic abdominal surgery
casodex/zoladex hormonal therapy study for assessment of correlation between psa & bai in prostate cancer patients

Conditions: Prostate Cancer

Summary: this study is an observational study to see whether anxiety level can be correlated with psa level under the current practice in the patients of prostate cancer taking hormonal therapy. for assessment of anxiety level bai(beck anxiety inventory) will be used. the target population for this study is the patients of prostate cancer diagnosed previously and who are taking hormonal therapy with regular follow-up and psa test. the follow-up duration will be total 6 months with interim visit at 3 month and final visit at 6 month.


Eligibility criteria:
inclusion criteria: 1. provision of written informed consent 2. patients who take psa test regularly 3. observation suitable patients for psa change according to hormonal treatment at least for 6months 4. locally advanced or advanced prostate cancer patients who is suitable for hormonal therapy 5. prostate cancer patients who has been taking one treatment among 3 hormonal therapies in below: * bicalutamide monotherapy : bicalutamide 150mg/day * goserelin 3.6mg/10.8mg * mab(maximal androgen blockade) :bicalutamide 50mg + goserelin 3.6/10.8mg exclusion criteria: 1. prohibition use under permitted indication 2. previous inclusion in the present study 3. participation in a clinical study during the last 30 days

Keywords: beck anxiety inventory prostate cancer prostate specific antigen naturalistic observational
qlb and laparoscopic nephrectomy, postoperative pain and recovery

Conditions: Postoperative Pain; Chronic Pain Post-Proceduraal; Nausea and Vomiting, Postoperative

Summary: there are ca 900 new cases of kidney cancer in finland/year. the curative therapy for kidney cancer is partial or total nephrectomy depending on the localization and the size of tumor. main of these operations are laparoscopic. epidural analgesia is considered as most effective for the treatment of postoperative pain after open nephrectomy, but after laparoscopic operation parenteral and enteral opioids combined with paracetamol (acetaminophen) usually offer adequate postoperative pain relief. however, the need for opioids postoperatively may be high and side effects, such as sedation and nausea, are common. on the other hand epidural analgesia has some contraindications and risks for serious complications. nevertheless, inadequately treated acute postoperative pain is considered as one of the main risk factors for persistent postoperative pain. recently quadratus lumborum block (qlb) has gained popularity in the treatment of postoperative pain after various surgeries in the area from hip to mamilla. it is more beneficial than other peripheral blocks, since it covers also the visceral nerves. a single shot qlb has reported to last up to 48 hours. perineural dexamethasone added to local anesthetic has been reported to prolong the duration of analgesia of the perineural nerve block, but it's effect on the duration of qlb is not known. 90 kidney cancer patients with planned laparoscopic nephrectomy aging 18-85 will be recruited based on a power calculation. the primary outcome measure is the postoperative cumulative opioid consumption. secondary outcomes are acute pain (nrs scale), nausea, vomiting, mobilisation and long term outcomes such as quality of life and persistent pain.


Eligibility criteria:
inclusion criteria: * patients with renal cancer coming to the laparoscopic radical nephrectomy exclusion criteria: * age under 18y or over 85y * diabetes type 1 with complications * no co-operation or inadequate finnish language skills * persistent pain for other reason * severe hepatic insufficiency or paracetamol (acetaminophen) is contraindicated for other reason * any type of steroid in regular use * oxycodone contraindicated * medications changing notably paracetamol (acetaminophen) and/or ropivacaine metabolism in regular use
drug eluting balloon in peripheral intervention for below-the-knee arteries with freeway and lutonix

Conditions: Peripheral Artery Disease

Summary: the aim of this study is to compare in patients with critical limb ischemia the efficacy of angioplasty with different paclitaxel-eluting balloon devices for below-the-knee lesions in terms of restenosis.

two devices will be evaluated: the lutonix and the freeway paclitaxel eluting balloons. a post-hoc analysis will compare the results with the historical data from debate-btk (nct01558505).

Eligibility criteria:
inclusion criteria: * age\>18 years * angiographic stenosis\>50% or occlusion of one below-knee vessel exclusion criteria: * allergy to paclitaxel * contraindication for combined antiplatelet treatment * life expectancy \<1 year * hypersensitivity or contraindication to one of the study drugs * lack of consent * need for amputation
sierra high definition ano-rectal manometry

Conditions: Constipation; Fecal Incontinence

Summary: hypotheses: high definition manometry (hdm) is safe and feasible in humans; hdm accurately characterizes anorectal anatomy and function in healthy humans; hdm provides comparable information regarding the structure and function of the anorectal region, to that obtained from ano-rectal manometry and anal ultrasonography (aus), in patients with fecal incontinence or constipation. methods: 20 healthy volunteers, 20 patients with fecal incontinence, 20 patients with constipation will be recruited. because anorectal disorders are more common in women, the investigators will recruit approximately 8 men and 12 women in each group. each subject will undergo anorectal manometry, anal ultrasound and high definition manometry. data analysis: spearman correlational analysis will be performed to compare the parameters listed above. also, the diagnostic yield of anal ultrasonography vs hdm in identifying anatomic sphincter defects will be assessed.


Eligibility criteria:
inclusion criteria: for patients: 1. either fecal incontinence (the occurrence of at least one episode of involuntary discharge of stool matter per week) or constipation (rome iii criteria) (16,17) 2. adults between the ages of 18-80 yrs. for healthy volunteers: 1. adults between the ages of 18-80 yrs 2. no gastrointestinal symptoms exclusion criteria: 1. rectal prolapse or anal fissure on physical examination 2. recent pelvic or recto-anal surgery (\< 6 months ago) 3. history of pelvic irradiation.
safety and efficacy evaluation of insight gs growing system

Conditions: Early Onset Scoliosis (EOS)

Summary: premarket, interventional, single-arm clinical study, to evaluate the safety and efficacy of insight gs growing system in the surgical treatment of early onset scoliosis (eos). also, to evaluate the difference in height of the spine and trunk, the success rate of the procedure, monitor adverse events and evaluate the satisfaction of the patient and care providers. the andromeda insight growing system (insight gs) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth. the andromeda insight growing system consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. the implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. the components are implanted from a posterior approach and are made from titanium alloy (ti6al-4v-eli), and high density polyethylene (hdpe). patients from 3 to 10 years of age, or who are still skeletally immature, who present early-onset scoliosis and who are considered as able to receive the surgical procedure with the insight gs system, will be included in the study. patients will be screened in the outpatient setting of the study site. all participants who meet the eligibility criteria will be invited to participate in the study, which includes screening/pre-op, surgery to install the insight gs system, and follow-up visits at 6 weeks, 2, 4, 6, 8, 10, 12,. 18 and 24 months for data collection, clinical evaluation, imaging, and monitoring of adverse events.


Eligibility criteria:
inclusion criteria: * tcle signed by parents * ages 3 to 10 years, or risser 0, or sanders 1,2,3 and 4 * cobb angle bigger than 30° * thoracic spine height t1-t12 less than 22 centimeters * risk of thoracic insufficiency syndrome (tis). exclusion criteria: * need for fixation at occipital or cervical levels * risser sign greater than or equal to 1 * sanders bigger than 4 * previous spine surgery * medullary abnormalities * existence of malignant processes * local or systemic inflammations and infections, acute or chronic * allergy or intolerance to materials * non-reducible scoliosis * morbid obesity * insufficiency or absence of skin coverage
international psychometric validation study of the intestinal gas questionnaire (igq)

Conditions: IBS - Irritable Bowel Syndrome; General Population

Summary: objective: to confirm the psychometrics properties of the intestinal gas questionnaire (igq) in subjects with irritable bowel syndrome (ibs) diagnosis and general population both complaining of gas-related symptoms (grs). igq has been developed previously simultaneously in uk english, french and spanish through qualitative research with subject interviews. the conceptual framework of the igq assesses both grs and their impact on daily life. similar concepts were identified for both subjects with ibs diagnosis and general population and complaining of gas-related symptoms. the igq consists of a 24-hour recall symptom diary assessing 7 gas-related symptoms (17 items) and a 7-day recall questionnaire which assesses the impact of those symptoms (26 items)

observational (non-interventional) study with a cross-sectional part for a subset of adult subjects with a single igq completion and a longitudinal cross-over part for a subset of subjects with test-retest igq completion for validation of electronic version of igq. 300 eligible subjects (100 in each of the 3 countries: france, uk \& spain): * 180 with ibs diagnosis (60% of recruited subjects) * 120 from general population (40% of recruited subjects)

Eligibility criteria:
inclusion criteria: all (subjects with ibs diagnosis and general population): * complaining of gas-related symptoms (grs) of a certain severity level: subjects with ibs diagnosis and general population need to report a score of 4 or greater on at least one symptom on the symptom screening tool * cognitive and linguistic capability to complete several self-questionnaires * bmi \> 18.5 and \< 30.0 kg/m2 * agreement of the subject to participate in the study subjects with ibs diagnosis: * ibs diagnosis using rome iii diagnostic criteria for functional gastrointestinal disorders (21) * ibs severity: ibs-sss score of 75 to 300 general population: * subjects not fulfilling ibs rome iii criteria * regular stool frequency (i.e., between 3 and 21 bowel movements per week) exclusion criteria all (subjects with ibs diagnosis and general population): * recent (2 last weeks) change in diet or intake of potentially flatulogenic compounds (fiber, lactulose) * organic gastrointestinal disease * other functional gastrointestinal disorder as defined by rome iii criteria * any severe and progressive disease (e.g. depression, cancer, uncontrolled diabetes, rheumatoid arthritis...) * any severe psychiatric disorder (e.g. acute episode of schizophrenia or bipolar disorder...) * pregnant women * being under the direct hierarchy of the investigatorbelonging to the site's staff team general population: * treatment for diarrhea or constipation including lactulose

Keywords: ibs, population
lucerne fall risk prediction score for stroke rehabilitation

Conditions: Stroke

Summary: in switzerland, every year around 16'000 people suffer a stroke. stroke represents the third most common cause of death in switzerland and leads to impairments (e.g., motoric, cognitive, sensory) resulting in disability. people with disabilities after stroke should have access to specialised interprofessional rehabilitation settings. during inpatient rehabilitation, 15-36% of the patients experience one or more falls. it is well known that stroke is an important risk factor for falls. on average stroke patients fall 1.77 times more than the age- and gender-matched controls over 13 months. falling events during inpatient stroke rehabilitation result in an extension of rehabilitation stay of about eleven days. wong et al. (2016) suspect that a reduction in the activity level due to falls, fear of falling again as well as changes in discharge conditions could be the reason for this extended length of stay. walsh et al. (2018) demonstrate that patients who fall once within the first year after stroke cause € 8'600 and recurrent fallers € 12'700 higher healthcare costs. fall risk factors after stroke are well investigated. campbell \& matthews (2010) have collected multiple factors for falls in inpatient stroke rehabilitation from 1990 to 2009 in an integrative review. a newer systematic review points out physical function, hemi-attention, and stability as the most important factors for falls in inpatient stroke rehabilitation. however, none of the included studies showed a validated prediction model with acceptable performance. hence, further investigations regarding the impact of various valid and reliable fall risk assessments at admission in inpatient rehabilitation are needed. the neurorehabilitation team of luks systematically assesses the patient's functions and activity to design patient-specific, evidence-based rehabilitation. therefore, a population-specific fall risk model based on standardized assessments performed in the clinical routine would help to identify patients with a high risk of falling during rehabilitation without the need of implementing an existing model with a low performance. aim of the study the main aim of this study is to establish a multivariable prediction model for falls during inpatient rehabilitation in acute and subacute stroke patients admitted to the clinic for neurology and neurorehabilitation of the kantonsspital luzern (luks) in lucerne, switzerland. the secondary aim is to explore the value of the mini-bestest as a fall predictor in a subgroup consisting of patients who are ambulatory at admission to the clinic for neurology and neurorehabilitation.


Eligibility criteria:
inclusion criteria: * acute/ subcute first or recurrent stroke * inpatient rehabilitation * signed general consent exclusion criteria: - re-rehabilitation due to a chronic stroke
according ctc to compare the influences of different methods to remove the pdac

Conditions: Carcinoma, Pancreatic Ductal; Circulating Tumor Cells

Summary: acccording circulating tumor cells to compare the differences of different methods(routine method、no-touch principle method、laparoscopy method) to remove the ductal adenocarcinoma of pancreatic body and tail.


Eligibility criteria:
inclusion criteria: * ductal adenocarcinoma of pancreatic body and tail * tumor can be removed * no other tumors and without liver metastases * age from 18 to 80 years old exclusion criteria: * neoplasms with other sites of the pancreas * with other tumors of any other sites